JP2020075926A5 - - Google Patents

Download PDF

Info

Publication number
JP2020075926A5
JP2020075926A5 JP2020002597A JP2020002597A JP2020075926A5 JP 2020075926 A5 JP2020075926 A5 JP 2020075926A5 JP 2020002597 A JP2020002597 A JP 2020002597A JP 2020002597 A JP2020002597 A JP 2020002597A JP 2020075926 A5 JP2020075926 A5 JP 2020075926A5
Authority
JP
Japan
Prior art keywords
seq
complementarity determining
determining regions
chain complementarity
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020002597A
Other languages
English (en)
Japanese (ja)
Other versions
JP6916319B2 (ja
JP2020075926A (ja
Filing date
Publication date
Priority claimed from JP2017515768A external-priority patent/JP6694877B2/ja
Application filed filed Critical
Publication of JP2020075926A publication Critical patent/JP2020075926A/ja
Publication of JP2020075926A5 publication Critical patent/JP2020075926A5/ja
Application granted granted Critical
Publication of JP6916319B2 publication Critical patent/JP6916319B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020002597A 2014-09-23 2020-01-10 抗il−25抗体およびその使用 Active JP6916319B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462054167P 2014-09-23 2014-09-23
US62/054,167 2014-09-23
JP2017515768A JP6694877B2 (ja) 2014-09-23 2015-09-22 抗il−25抗体およびその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017515768A Division JP6694877B2 (ja) 2014-09-23 2015-09-22 抗il−25抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2020075926A JP2020075926A (ja) 2020-05-21
JP2020075926A5 true JP2020075926A5 (https=) 2020-07-27
JP6916319B2 JP6916319B2 (ja) 2021-08-11

Family

ID=54207847

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017515768A Active JP6694877B2 (ja) 2014-09-23 2015-09-22 抗il−25抗体およびその使用
JP2020002597A Active JP6916319B2 (ja) 2014-09-23 2020-01-10 抗il−25抗体およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017515768A Active JP6694877B2 (ja) 2014-09-23 2015-09-22 抗il−25抗体およびその使用

Country Status (18)

Country Link
US (3) US9840557B2 (https=)
EP (1) EP3197914B1 (https=)
JP (2) JP6694877B2 (https=)
KR (1) KR102576368B1 (https=)
CN (1) CN107207589B (https=)
AU (1) AU2015321517B2 (https=)
CA (1) CA2961517C (https=)
CL (2) CL2017000703A1 (https=)
CO (1) CO2017003072A2 (https=)
EA (1) EA036658B1 (https=)
IL (1) IL251001B (https=)
MA (1) MA40106A1 (https=)
MX (1) MX2017003841A (https=)
MY (1) MY185832A (https=)
PH (1) PH12017500403A1 (https=)
SG (2) SG10201913084PA (https=)
WO (1) WO2016049000A2 (https=)
ZA (1) ZA201701663B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913084PA (en) 2014-09-23 2020-03-30 Regeneron Pharma Anti-il-25 antibodies and uses thereof
KR102460040B1 (ko) 2016-04-27 2022-11-01 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor
CN107213463A (zh) * 2017-05-24 2017-09-29 清华大学 白介素25在银屑病的发育中的作用
DE102017215154A1 (de) 2017-08-30 2019-02-28 Markus Bläss Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen
WO2020102935A1 (en) * 2018-11-19 2020-05-28 Suzhou Kanova Biopharmaceutical Co., Ltd. Anti-il-25 antibodies and use thereof
BR112022012093A2 (pt) 2019-12-20 2022-08-30 Momenta Pharmaceuticals Inc Anticorpos contra integrina alfa 11 beta 1
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
WO2022150660A1 (en) * 2021-01-08 2022-07-14 10X Genomics, Inc. Antigen-binding polypeptides specific for coronaviruses and uses thereof
US20240400671A1 (en) * 2021-10-05 2024-12-05 Richard A. Shimkets Monoconal antibodies to il-25 and uses thereof
JP2025508835A (ja) * 2022-02-24 2025-04-10 シノマブ バイオサイエンス リミテッド アラーミンに対する二重特異性結合タンパク質およびその使用
WO2023205612A1 (en) * 2022-04-18 2023-10-26 Access Medical Systems, Ltd. High sensitivity biolayer interferometry with enzyme amplification
CN119451698A (zh) * 2023-03-31 2025-02-14 新石生物制药有限公司 抗il-25抗体及其使用方法
WO2026067830A1 (zh) * 2024-09-30 2026-04-02 深圳市小分子新药创新中心有限公司 抗il-25单域抗体及其衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US7060802B1 (en) * 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
GB0707505D0 (en) * 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
HUE036157T2 (hu) * 2010-03-30 2018-06-28 Janssen Biotech Inc Humanizált IL-25 ellenanyagok
WO2012097126A2 (en) * 2011-01-13 2012-07-19 The University Of Maryland, Baltimore Il-25 treatment of obesity and metabolic disorders
JP2015521591A (ja) * 2012-06-12 2015-07-30 オレガ・バイオテック Il−17アイソフォームのアンタゴニストおよびその使用
SG10201913084PA (en) 2014-09-23 2020-03-30 Regeneron Pharma Anti-il-25 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2020075926A5 (https=)
JP2014237671A5 (https=)
Nirula et al. Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases
AU2008334605B2 (en) Polypeptides, antibody variable domains & antagonists
JP2019531273A5 (https=)
JP7434456B2 (ja) 抗il-13抗体を使用する、il-13活性が有害である疾患の治療方法
RU2640025C2 (ru) Способы и композиции для лечения астмы с использованием антител против il-13
JP2017079785A5 (https=)
Heck et al. Pharmacological therapy of bronchial asthma: the role of biologicals
CN107474134A (zh) 用于结合白细胞介素4受体的抗体
JP2017533888A5 (https=)
CN102037011A (zh) 用于治疗银屑病的方法
JP2016536327A5 (https=)
JP2025122028A (ja) Il-33アンタゴニストを投与することにより喘息を治療するまたは予防するための方法
JP2010515774A (ja) 乾せんの治療方法
JP2025164767A (ja) Il-33アンタゴニストを投与することによりcopdを治療するための方法
CN120958023A (zh) 通过阻断il-13和tslp治疗哮喘
Dandash et al. Targeting the double-edged sword: cytokines in the pathogenesis and treatment of autoimmune diseases
JP2017527546A (ja) 抗TNF−α抗体療法を受けた乾癬患者を治療するための方法
JPWO2021195530A5 (https=)
Imanirad et al. Current biologics in asthma treatment
de Oliveira et al. Immunobiological therapy in the treatment of severe asthma
NZ730105B2 (en) Anti-il-25 antibodies and uses thereof
CN118021955A (zh) 用于治疗il-17a介导的疾病或病症的方法和组合物
NZ730105A (en) Anti-il-25 antibodies and uses thereof